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ABOUT THE COVER
Galectin-1, a carbohydrate-binding protein, abundantly expressed at sites of
tumor growth and metastasis, promotes tumor progression by influencing
diverse cancer-related events including tumor cell migration, angiogenesis,
and tumor-immune escape. Dalotto-Moreno and colleagues show that
galectin-1 contributes to immunosuppression during progression of breast
cancer. Human breast cancer biopsies expressed substantial amounts of
galectin-1, which positively correlated with tumor grade. Silencing Gal1
expression in the 4T1 breast tumor model reduced tumor growth and lung
metastases. This effect was accompanied by a diminished frequency and
suppressive activity of CD4þCD25þ Foxp3þ regulatory T cells in both the
tumor and metastatic lungs. For details, see article by Dalotto-Moreno and
colleagues on page 1107.
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